CALCIUM GLUCONATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C6H11O7.Ca
Molecular Weight	430.373
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Ca++].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O

InChI

InChIKey=NEEHYRZPVYRGPP-IYEMJOQQSA-L

InChI=1S/2C6H12O7.Ca/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;/h2*2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t2*2-,3-,4+,5-;/m11./s1

HIDE SMILES / InChI

Molecular Formula	C6H11O7
Molecular Weight	195.1473
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including https://www.alfa.com/en/catalog/043674/

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Hypocalcemia 73 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 511	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 175 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 438	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 438	Unknown Approved Use Unknown
Unknown 2596
Hypocalcemia 73 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8583	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells.	2000 Aug	10970766
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells.	2000 Jun	10963052
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.	2000 Nov	11040061
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension.	2000 Sep	10993766
Chemokines induce eosinophil degranulation through CCR-3.	2000 Sep	10984371
ATP induces dephosphorylation of myosin light chain in endothelial cells.	2000 Sep	10942722
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.	2001 Apr 27	11278295
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations.	2001 Apr 7	11298490
Complement activation in factor D-deficient mice.	2001 Dec 4	11724962
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.	2001 Jun	11356925
Cloning and characterization of a novel human histamine receptor.	2001 Mar	11181941
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.	2001 Nov	11701772
Activating mutations of the calcium-sensing receptor: management of hypocalcemia.	2001 Nov	11701698
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.	2001 Nov 1	11705452
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.	2001 Oct 26	11679415
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.	2002 Dec	12456425
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.	2002 Feb	11796525
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.	2002 Jan 15	11809688
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.	2002 Nov 4	12445469
Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity.	2009 Jul-Aug	19567386
A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans.	2012 Apr	22019281
Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review.	2014 Jul	24705069
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.	2015 Sep 16	26376110
Lactose behaviour in the presence of lactic acid and calcium.	2016 Aug	27600977
Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate.	2018 Mar	28802019

Patents

Sample Use Guides

In Vivo Use Guide

Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:10 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:10 GMT 2025`
Record UNII	SQE6VB453K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALCIUM GLUCONATE ANHYDROUS

Preferred Name

English

CALCIUM GLUCONATE

Official Name

English

CALCAREA GLUCONICA

Common Name

English

E-578

Code

English

CALGLUCON

Brand Name

English

CALCIUM GLUCONATE [VANDF]

Common Name

English

CALCIUM GLUCONATE [FCC]

Common Name

English

CALCIUM GLUCONATE [MI]

Common Name

English

INS-578

Code

English

CALCIUM GLUCONATE [USP MONOGRAPH]

Common Name

English

CALCIUM GLUCONATE [ORANGE BOOK]

Common Name

English

CALCIUM GLUCONATE, ANHYDROUS

Common Name

English

CALCIUM GLUCONATE [WHO-IP]

Common Name

English

Calcium gluconate [WHO-DD]

Common Name

English

NSC-744619

Code

English

CALCIUM DI-GLUCONATE

Common Name

English

CALCIUM GLUCONATE [USP IMPURITY]

Common Name

English

D-GLUCONIC ACID, CALCIUM SALT (2:1)

Common Name

English

CALCIUM GLUCONATE, ANHYDROUS [EP MONOGRAPH]

Common Name

English

INS NO.578

Code

English

CALCII GLUCONAS [WHO-IP LATIN]

Common Name

English

CALCIUM GLUCONATE ANHYDROUS [USP-RS]

Common Name

English

CALCIUM GLUCONATE [HSDB]

Common Name

English

Classification Tree Code System Code

WHO-ATC

A12AA03